Asuragen has introduced miRInform Pancreas test to diagnose and manage pancreatic ductal adenocarcinoma (PDAC) when cytology is indeterminate.
The test assess expression levels of seven miRNAs in fine needle aspirate (FNA) specimens of pancreatic masses.
The study, conducted by the company and many pancreatic physicians, demonstrated that the miRInform test was able to accurately resolve over 75% of the FNAs that were indeterminate by cytology, which comprised approximately 13% of the samples in the study.
miRInform also identified more than half of the PDAC samples within the 30% false negative samples resulting from cytology alone.
The test had an overall accuracy of over 77% and a positive predictive value (PPV) of 86.5% for samples determined by cytology to be benign or indeterminate.
The company said the results helps in improving the diagnosis of PDAC and permit the selection of the most appropriate treatment for these patients.